Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. Aimovig contains the active substance erenumab.
Therapeutic Indication
Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.
Therapeutic Area (MeSH)
ATC Code
N02CD01
ATC Item
N/A
Pharmacotherapeutic Group
Analgesics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| erenumab | N/A | erenumab |
EMA Name
Aimovig
Medicine Name
Aimovig
Aliases
N/ANo risk management plan link.
